objective To examine trends in prescription of cough medicines over the period 2002-2015 in children aged 1 month to 12 years admitted to Kenyan hospitals with cough, difficulty breathing or diagnosed with a respiratory tract infection. conclusions There has been an overall decline in the use of cough medicines among hospitalised children over time. This decline has been associated with educational, policy and mass media interventions.
Introduction
Cough is a common symptom in children presenting with respiratory tract infections. It tends to cause anxiety to caregivers, discomfort to the child [1] , and physicians are usually under pressure to prescribe medication for symptomatic relief contrary to treatment guidelines [2] [3] [4] . Medications used include mucolytic agents (to reduce the thickness of mucus), decongestants and antitussives (to suppress cough). Cough suppression may lead to accumulation of secretions, airway obstruction and hypoxaemia [5, 6] . Some cough medications contain active ingredients that have been associated with serious adverse reactions including arrhythmias, behavioural disturbances, respiratory depression and even death [5, 7, 8] . Many studies, mainly in Europe and North America, have shown widespread use of cough mixtures, mainly decongestants and antitussive medications [9] and report that up to 6% of all visits to the emergency department could be secondary to adverse drug events in children under 12 years using cough medicines [10] .
There have been varied efforts to improve care and guideline compliance for treatment of respiratory infections in Kenya over a number of years. These include the initial introduction and scale up of the Integrated Management of Childhood Illness (IMCI) from 1999, introduction and scale up of Emergency Triage Assessment and Treatment plus admission care (ETAT+) training targeting hospital-based care from 2006 and efforts at disseminating policy through the media (2009) to discourage prescription of cough mixtures to children [11, 12] . There have, however, been few reports on the use of cough medication in children in the sub-Saharan region, and most have examined their use in outpatient settings [13] . Three prior studies in Kenyan hospitals using standardised methods [14] [15] [16] [17] and ongoing inpatient surveillance in paediatric wards in 13 Kenyan county hospitals [18] present an opportunity to examine trends in prescription of cough mixtures over the period [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] in ill children admitted to hospital for whom risks of adverse effects may be higher. Although behaviour change at scale may take time to manifest, it is unusual to have longitudinal data from a low-income setting. This report presents such data that may be of wider relevance given current concerns on how to reduce unnecessary antibiotic use.
Methods

Setting
The study uses data collected using a consistent method as part of four research studies in Kenya that provide data from six time points between 2002 and 2015 [15] [16] [17] [18] [19] . These studies were carried out in hospital facilities located in a district's (now county) main town, which provide first referral care. Surveys were conducted in collaboration with the Ministry of Health as part of research examining the quality of paediatric care. Facilities across Kenya were purposefully sampled to meet the needs of the particular survey (Table 1) . Children in these facilities are expected to be under the care of general medical officers and clinical officers (non-physician clinicians) under the supervision of a paediatrician who is responsible for inpatient prescribing, one focus of the surveys. In all the surveys, a similar approach to training data collectors to review medical records of children after discharge was used (comprising workshops, pilot exercises and use of standard operating procedures), similar data elements were collected, and data collection was supervised with procedures for quality assurance employed. We have previously shown that collecting these data from archived records provides the same results as collecting data while children are admitted [17] . The data used in the analyses reported included demographic data, documented clinical signs and symptoms, vital signs, the admission drugs prescribed and the clinical outcome [20] . In an effort to standardise the type of care being evaluated, we excluded one facility in the 2013-2015 survey as care is provided by non-physician clinicians, there are no qualified doctors and it is a large demonstration health centre with few inpatient beds rather than being a county referral hospital. A summary of the surveys and the hospital selection process is shown in Table 1 . All studies were approved by the Kenyan Ministry of Health and had ethical approval from the Kenya Medical Research Institute.
Study population and data analysis
We used de-identified data from all children from 1 month to 12 years admitted with symptoms of cough or difficulty in breathing or a diagnosis of an upper or lower respiratory tract infection based on the ICD 10 criteria [21] (Table S1 ). The analysis excluded children with a diagnosis indicating an atopic illness, as these children may have been given antihistamines as part of their treatment (Table S2) . We included children with a diagnosis of asthma so as to capture the (inappropriate) use of oral bronchodilators, which is currently not recommended due to the adverse effects. Inhaled bronchodilators are the treatment of choice for asthma in children [22] . Amongst eligible children, we determined the proportion prescribed any adjuvant medication for cough. To do this, we matched the names of each child's prescribed drugs against published lists of medicines available in Kenya and formularies to determine their active ingredients. We classified active ingredients in these medicines (referred to as a group as cough medicines) into five categories: antihistamines, antitussives, mucolytics/expectorants, decongestants and bronchodilators [23] ( Table S3 ). The data are summarised as the proportion of children admitted with a respiratory illness with at least one cough medicine calculating 95% confidence intervals (95% CI) around this estimate and presenting the result graphically. We further explored the pattern of active ingredients used over time using graphical methods. In these latter analyses, each active ingredient was counted such that a medicine containing three active compounds would contribute 1 count in each of three categories of ingredients.
Ethical approval
The findings reported here derive from data collected in three studies that were individually approved by The KEMRI Scientific and Ethics Review committees.
Results
The median age and length of the hospital stay of the participants were comparable across the data sets. However, children included less frequently had cough in later studies (2013 and 2015), and fever was more prevalent in some surveys (2006 and 2008) . Mortality also varied across the studies from 4.7% to 10.2%. Table 2 summarises data on the populations of children included in each study. Figure 1 .
Cough medicine prescription trends
Cough medicine contents
Across the surveys, the most common active ingredients in prescribed cough medicines were antihistamines and bronchodilators. Between 2006 and 2012, cough medicines containing oral bronchodilators constituted the bulk of prescriptions. Amongst children prescribed a cough medicine, the proportion that include antihistamines as active ingredients increased over time, constituting over half of the prescriptions in the 2013 and 2015 surveys. Prescription of decongestant-containing medicines remained relatively infrequent across the studies (Figure 2) . The prescriptions containing antitussives were very few and are not included in the figure.
Discussion
There has been a general decline in the prescription rates for cough medicines across the fourteen years from 40% in 2002 to 6% in 2015 for children admitted to general district (now county) hospitals with cough, difficulty breathing or diagnosed with an upper respiratory infection. This is despite the low cost of cough medicines and continuing aggressive marketing by manufacturers in Kenya, which has been identified as one of the reasons why cough medicines are prescribed. It has also been suggested that health workers have a poor understanding of the ingredients in cough medicines [13] . This suggests that marketing or some perceived benefit of active ingredients where they are known might influence changes in the pattern of active ingredients over time. Accompanying an overall decline in cough medicine prescribing was a shift across the surveys first towards bronchodilator and then towards antihistamine-containing cough medicines. This may be due to more effective marketing of newer generation antihistamine medications said to have better safety profiles [24] . In earlier surveys, children prescribed a cough medicine containing bronchodilators may often have been prescribed inhaled beta-agonists as specific treatment too (unpublished observation). The later decline in use of cough medicines containing bronchodilators may, we speculate, be linked to efforts to improve awareness of the appropriate use of inhaled bronchodilators for asthma and that oral bronchodilators are of limited effectiveness. Across the time period spanning the surveys and the decline in cough medicine use, there have been a number of initiatives that may have influenced prescribing habits (Table 3 ). In addition to these, there has been an improvement in clinical staffing numbers and the cadre of clinical staff in charge of the paediatric wards has slowly changed. In 2002, with few paediatricians in the country, most inpatient paediatric care was led by clinical officers (non-physician clinicians) supervised by general medical officers. However, by the 2013-2015 survey, inpatient paediatric care in county hospitals, including the 13 in this study, was often led by a consultant paediatrician assisted by several intern medical officers and sometimes a general medical officer [25] . Many of these medical officers and paediatricians were trained in use of and have access to national guidelines [26] , with the training typically emphasising that cough medicines are contraindicated. We speculate therefore that some of the decline in use of cough medicines for the inpatient population is attributable to greater presence in hospitals of junior physicians and consultant paediatricians educated not to use cough medicines. Such staff would also have been target recipients of updated pneumonia guideline dissemination after the 2013 revisions when a notable decrease in cough medicine use occurred. (Figure 1 ) Interestingly, a review of the prescriptions from the excluded health facility, where all patient care is provided by nonphysician clinicians, revealed a larger number of cough medicine prescriptions amongst those admitted for care for pneumonia, averaging about 14% for the two periods (2013 and 2015) . This study had a number of limitations. Purposive sampling of hospitals was employed for each survey, and there was no pre-specified aim to track use of unnecessary medicines across time. Each study also provided different samples sizes for analysis, and the data were collected by different teams in the individual studies even though similar tools were used. Based on the data collected, we are unable to determine the doses of the medicines prescribed, the frequency of administration or whether any adverse events occurred as a result of the prescriptions. Furthermore, it is possible that some prescriptions for cough medicines were not recorded in hospital records but given directly to parents. In the 2013-2015 survey, we noted an increase in the prescription of cough medicines between the two six-month periods sampled. A reduction in levels of missing data on other parameters of interest within the clinical information network has been noted over this period [27] . An improvement in the capture of data on cough medicines may therefore be contributing to their apparent increase in use.
Despite these limitations, we feel that the decline in the prescription of cough medicines observed across surveys in hospitalised children in Kenya is likely to reflect a true change in practice over a period of 14 years. We suggest that reducing exposure of already sick hospitalised children to their potential adverse events is likely therefore to have helped improve patient safety and reduced healthcare costs. As most cough remedies may be provided to ambulant children as over the counter or outpatient prescriptions, examination of cough mixture use among these groups of children would also be useful to provide a more complete picture of the situation in Kenya and other countries.
Conclusion
There has been an overall decline in the use of cough medicines among hospitalised children across Kenyan hospitals over time. This decline has been associated with educational, policy and mass media interventions and an expansion of the physician and specialist paediatric workforce. We believe the findings help demonstrate the value of long-term surveillance of prescribing habits that may be of particular value in an era when there is increasing concern around rational treatment use and stewardship. 
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